natgillin/translations-raw huggingface dataset:
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 mL of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation (see Posology, “Adult haemodialysis patients”). 
Alternativno, injekcija se može dati na kraju postupka dijalize putem sustava igle za fistulu, nakon čega treba dati 10 ml izotonične otopine natrijevog klorida radi ispiranja sustava i osiguranja optimalnog ulaska lijeka u cirkulaciju (vidjeti Doziranje, „Odrasli bolesnici na hemodijalizi“).
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). 
Metaanalizom podataka o ukupnom preživljenju procijenilo se da je točkovna procjena omjera hazarda 1,06 u korist kontrolnih ispitanika (95 % CI: 1,00, 1,12; 53 ispitivanja i 13 933 bolesnika), dok je u onkoloških bolesnika koji su primali kemoterapiju, ukupni omjer hazarda preživljenja iznosio 1,04 (95 % CI: 0,97, 1,11; 38 ispitivanja i 10 441 bolesnik).
Further pharmacodynamic studies explored 40,000 IU once weekly versus 150 IU/kg 3 times per week. 
Daljnja farmakodinamička ispitivanja istraživala su primjenu 40 000 IU jednom tjedno naspram sa 150 IU/kg 3 puta tjedno.
Patients should be monitored closely to ensure that the lowest approved effective dose of Epoetin alfa HEXAL is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dL (7.5 mmol/L). 
Bolesnike treba pažljivo pratiti kako bi se osigurala primjena najniže odobrene učinkovite doze Epoetin alfa HEXALa koja pruža odgovarajuću kontrolu anemije i simptoma anemije, uz istovremeno održavanje koncentracije hemoglobina ispod ili na 12 g/dl (7,5 mmol/l).
The recommended maintenance dose is between 25 IU/kg and 50 IU/kg, 2 times per week in 2 equal injections. 
Preporučena doza održavanja je između 25 IU/kg i 50 IU/kg 2 puta tjedno u 2 jednake injekcije.
In patients with a poor haemoglobin response to Epoetin alfa HEXAL, alternative explanations for the poor response should be considered (see section 4.4 and 5.1). 
U bolesnika sa slabim odgovorom hemoglobina na Epoetin alfa HEXAL, potrebno je razmotriti druga moguća objašnjenja za slab odgovor (vidjeti dio 4.4 i 5.1).
However the product is for single use only. 
Međutim, lijek je namijenjen samo za jednokratnu primjenu.
These include venous and arterial thromboses and embolism (including some with fatal outcomes), such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, and myocardial infarction. 
Oni obuhvaćaju vensku i arterijsku trombozu i emboliju (uključujući pojedine slučajeve sa smrtnim ishodom), kao što su duboka venska tromboza, plućna embolija, tromboza retinalne vene i infarkt miokarda.
Alternatively, Epoetin alfa HEXAL can be administered at an initial dose of 450 IU/kg subcutaneously once weekly. 
Alternativno se Epoetin alfa HEXAL može primijeniti u početnoj dozi od 450 IU/kg supkutano jedanput tjedno.
Only take one dose of Epoetin alfa HEXAL from each syringe discarding unwanted solution before injection. 
Uzmite samo jednu dozu lijeka Epoetin alfa HEXAL iz svake štrcaljke i nepotrebnu otopinu bacite prije primjene injekcije.
Shunt thromboses have occurred in haemodialysis patients, especially in those who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurysms, etc.). 
U bolesnika na hemodijalizi pojavila se tromboza arteriovenskog spoja, osobito u onih koji su bili skloni hipotenziji ili su imali komplikacije arteriovenske fistule (npr. stenoze, aneurizme itd.).
The reported risk of these TVEs should be carefully weighed against the benefits to be derived from treatment with epoetin alfa particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs (e.g. deep venous thrombosis, pulmonary embolism, and cerebral vascular accident). 
Zabilježeni rizik od ovih TVD-ova treba pažljivo procijeniti u odnosu na koristi koje se mogu dobiti od liječenja epoetinom alfa, osobito u bolesnika s već prisutnim čimbenicima rizika za TVD, uključujući pretilost i TVD-i u anamnezi (npr. duboka venska tromboza, plućna embolija ili cerebralni vaskularni incident).
Epoetin alfa was administered at 75 IU/kg/week intravenously in 2 or 3 divided doses post-dialysis, titrated by 75 IU/kg/week at intervals of 4 weeks (up to a maximum of 300 IU/kg/week), to achieve a 1 g/dL/month increase in haemoglobin. 
Epoetin alfa primjenjivao se intravenski u dozi od 75 IU/kg/tjedno podijeljeno u 2 ili 3 doze nakon dijalize i titrirano od po 75 IU/kg/tjedno u intervalima od 4 tjedna (do najviše 300 IU/kg/tjedno) kako bi se postigao porast hemoglobina od 1 g/dl/mjesečno.
Patients were stratified according to their baseline haemoglobin (≤ 10 g/dL, > 10 to ≤ 13 g/dL and > 13 g/dL). 
Bolesnici su podijeljeni u skupine prema početnoj razini hemoglobina (≤ 10 g/dl, > 10 do ≤ 13 g/dl i > 13 g/dl).
Always keeping your skin pinched, depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. 
Držeći i dalje nabor kože između prstiju, polako i jednolično potisnite klip sve dok niste dali cijelu dozu i klip se ne može dalje potisnuti.
• The starting dose is either 150 IU per kilogram body weight three times a week or 450 IU per kilogram body weight once a week. 
• Početna doza je 150 IU po kilogramu tjelesne težine tri puta tjedno ili 450 IU po kilogramu tjelesne težine jednom tjedno.
Comparable intensity of chemotherapy in the epoetin alfa and placebo groups in the chemotherapy trials was demonstrated by a similar area under the neutrophil time curve in patients treated with epoetin alfa and placebo-treated patients, as well as by a similar proportion of patients in groups treated with epoetin alfa and placebo-treated groups whose absolute neutrophil counts fell below 1,000 and 500 cells/µL. 
Usporediv intenzitet kemoterapije u skupinama koje su primale epoetin alfa i skupinama koje su primale placebo u ispitivanjima s kemoterapijom dokazan je sličnom površinom ispod krivulje broja neutrofila-vrijeme u bolesnika koji su primali epoetin alfa i bolesnika koji su primali placebo, kao i sličnim udjelom bolesnika čiji je apsolutni broj neutrofila pao ispod 1000 i 500 stanica/µl u skupinama koje su liječene epoetinom alfa i skupinama koje su primale placebo.
This was a non inferiority study designed to rule out a 15% risk increase in tumour progression or death of epoetin alfa plus standard of care (SOC) as compared with SOC alone. 
To je bilo ispitivanje neinferiornosti ustrojeno tako da se isključi 15 %-tno povećanje rizika od progresije tumora ili smrti u skupini liječenoj epoetinom alfa plus standardna terapija u usporedbi sa samo standardnom terapijom.
Similar rates of rise of haematocrit were noted when epoetin alfa was administered by either route. 
Slične stope porasta hematokrita bile su zabilježene pri primjeni epoetina alfa bilo kojim putem primjene.
Hypertension, Venous and arterial thromboses2 
Krvožilni poremećaji hipertenzija, venska i arterijska tromboza2
In a study comparing the 150 IU/kg, 3 times per week and 40,000 IU, once-weekly dosing regimens in healthy subjects and in anaemic cancer subjects the time profiles of changes in percent reticulocytes, haemoglobin, and total red blood cells were similar between the two dosing regimens in both healthy and anaemic cancer subjects. 
U ispitivanju koje je usporedilo primjenu 150 IU/kg 3 puta tjedno i 40 000 IU jednom tjedno u zdravih ispitanika i anemičnih ispitanika s rakom, profili promjena postotka retikulocita, hemoglobina i ukupnog broja crvenih krvnih stanica tijekom vremena bili su slični u ta dva režima doziranja i u zdravih ispitanika i u anemičnih ispitanika s rakom.
Epoetin alfa HEXAL 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2,000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10,000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40,000 IU/1 mL solution for injection in a pre-filled syringe 
Epoetin alfa HEXAL 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 2000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 3000 IU/0,3 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 4000 IU/0,4 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 6000 IU/0,6 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 7000 IU/0,7 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 8000 IU/0,8 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 9000 IU/0,9 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 20 000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 30 000 IU/0,75 ml otopina za injekciju u napunjenoj štrcaljki Epoetin alfa HEXAL 40 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
- For patients scheduled for major elective orthopaedic surgery, iron supplementation (elemental iron 200 mg/day orally) should be administered throughout the course of epoetin alfa therapy. 
U odraslih bolesnika predviđenih za veliki elektivni ortopedski kirurški zahvat, nadoknada željeza (elementarno željezo, 200 mg/dan peroralno) treba se primijeniti tijekom trajanja terapije epoetinom alfa.
25, D-83607 Holzkirchen, Germany 
Hexal AG, Industriestr. 25, D-83607 Holzkirchen, Njemačka
• You may be given iron supplements before and during Epoetin alfa HEXAL treatment to make it more effective. 
• Možda ćete prije i tijekom terapije Epoetin alfa HEXALom dobivati dodatke sa željezom kako bi liječenje bilo djelotvornije.
Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician's evaluation of the individual patient's clinical course and condition is necessary. 
Simptomi anemije i njezine posljedice mogu se razlikovati ovisno o dobi, spolu i drugim istodobno prisutnim bolestima; neophodna je liječnička procjena kliničkog tijeka bolesti i stanja pojedinog bolesnika.
After single doses (20,000 to 160,000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin. 
Nakon jednokratnih doza (20 000 do 160 000 IU supkutano) epoetina alfa uočen je odgovor ispitivanih farmakodinamičkih biljega ovisan o dozi uključujući: retikulocite, crvene krvne stanice i hemoglobin.
Epoetin alfa HEXAL is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements. 
Epoetin alfa HEXAL je indiciran u odraslih koji primaju kemoterapiju zbog solidnih tumora, malignog limfoma ili multiplog mijeloma, te kod kojih postoji rizik od transfuzije prema procjeni njihovog općeg stanja (npr. kardiovaskularni status, anemija koja je prisutna na početku kemoterapije), za liječenje anemije i smanjenje potrebe za transfuzijom.
- an observed 9% increase in risk for progress of disease (PD) or death in the epoetin alfa plus SOC group from a primary analysis and a 15% increased risk that cannot be statistically ruled out in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 10 to 12 g/dL (6.2 to 7.5 mmol/L). 
- opaženo 9 %-tno povećanje rizika za progresiju bolesti ili smrt u skupini liječenoj epoetinom alfa plus standardna terapija iz primarne analize i rizik povećan za 15 % koji se statistički ne može isključiti u bolesnica s metastatskim rakom dojke koje su primale kemoterapiju, kada se primjenjivao s ciljem postizanja raspona koncentracije hemoglobina od 10 do 12 g/dl (6,2 do 7,5 mmol/l).
PRCA means the bone marrow does not make enough red blood cells. 
Izolirana aplazaija crvene loze znači da koštana srž ne stvara dovoljno crvenih krvnih stanica.
Patients with very low initial haemoglobin (< 6 g/dL or < 3.75 mmol/L) may require higher maintenance doses than patients whose initial anaemia is less severe (> 8 g/dL or > 5 mmol/L). 
Bolesnicima s vrlo niskom početnom razinom hemoglobina (< 6 g/dl ili < 3,75 mmol/l) mogu biti potrebne više doze održavanja nego bolesnicima čija je početna anemija manje teška ( > 8 g/dl ili > 5 mmol/l).
Cases have also been reported in patients with hepatitis C treated with interferon and ribavirin, when ESAs are used concomitantly. 
Slučajevi su prijavljeni i u bolesnika s hepatitisom C liječenih interferonom i ribavirinom, kod istodobne primjene lijekova za stimulaciju eritropoeze.
• Your doctor will maintain your haemoglobin level between 10 and 12 g/dL as a high haemoglobin level may increase the risk of blood clots and death. 
• Liječnik će održavati razinu Vašeg hemoglobina između 10 i 12 g/dl jer visoka razina hemoglobina može povećati rizik od krvnih ugrušaka i smrti.
Of a total 3,417 subjects in 25 randomised, double-blinded, placebo or standard of care controlled studies, the overall safety profile of epoetin alfa was evaluated in 2,094 anaemic subjects. 
Od ukupno 3417 ispitanika u 25 randomizirana, dvostruko slijepa ispitivanja kontrolirana placebom ili standardnom terapijom, opći sigurnosni profil epoetina alfa procijenjen je u 2094 ispitanika s anemijom.
Treatment of adult patients with low- or intermediate-1-risk MDS 
Liječenje odraslih bolesnika s MDS-om niskog ili srednjeg-1 rizika
Epoetin alfa has been studied in clinical trials in adult anaemic CRF patients, including haemodialysis and pre-dialysis patients, to treat anaemia and maintain haematocrit within a target concentration range of 30 to 36%. 
Epoetin alfa ispitivan je u kliničkim ispitivanjima u odraslih anemičnih bolesnika s KZB, uključujući bolesnike na dijalizi i one koji još nisu na dijalizi, za liječenje anemije i održavanje hematokrita unutar ciljnog raspona koncentracije od 30 do 36 %.
The AUCs of the respective pharmacodynamic parameters were similar between the 150 IU/kg, 3 times per week and 40,000 IU, once-weekly dosing regimens in healthy subjects and also in anaemic cancer subjects. 
AUC odgovarajućih farmakodinamičkih parametara bio je sličan u režimu doziranja 150 IU/kg 3 puta tjedno i 40 000 IU jednom tjedno kako u zdravih ispitanika, tako i u anemičnih ispitanika s rakom.
Before use, leave the Epoetin alfa HEXAL syringe to stand until it reaches room temperature. 
Prije primjene, ostavite štrcaljku Epoetin alfa HEXALa izvan hladnjaka dok ne postigne sobnu temperaturu.
Epoetin alfa 300 IU/kg significantly reduced the risk of allogeneic transfusion in patients with a pretreatment haemoglobin of > 10 to ≤ 13 g/dL. 
Epoetin alfa u dozi od 300 IU/kg značajno je smanjio rizik od alogene transfuzije u bolesnika s razinom hemoglobina prije početka liječenja od > 10 do ≤ 13 g/dl.
• Arm or leg pain. 
• Bol u ruci ili nozi
- For chronic renal failure patients, iron supplementation (elemental iron 200 to 300 mg/day orally for adults and 100 to 200 mg/day orally for paediatrics) is recommended if serum ferritin levels are below 100 ng/mL. 
Za bolesnike s kroničnim zatajenjem bubrega preporučuje se nadoknada željeza, (elementarno željezo, 200 do 300 mg/dan peroralno za odrasle i 100 do 200 mg/dan peroralno za pedijatrijske bolesnike) ako su razine feritina u serumu manje od 100 ng/ml.
Apply pressure over the injection site with a dry, sterile pad. 
Pritisnite mjesto primjene injekcije suhim, sterilnim tupferom.
4.3 Contraindications - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
- Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1.
Epoetin alfa should be used with caution in patients with porphyria. 
Epoetin alfa treba primjenjivati s oprezom u bolesnika s porfirijom.
In addition, thrombocythaemia above the normal range has been reported. 
zabilježena je i trombocitemija iznad normalnog raspona.
> 13 g/dL (> 8.1 mmol/L), the possibility that epoetin alfa treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. 
Štoviše, u bolesnika s početnom vrijednošću hemoglobina > 13 g/dl (> 8,1 mmol/l), ne može se isključiti mogućnost povezanosti liječenja epoetinom alfa s povećanim rizikom od postoperativnih trombotskih/vaskularnih događaja.
What Epoetin alfa HEXAL looks like and contents of the pack 
Kako Epoetin alfa HEXAL izgleda i sadržaj pakiranja
Epoetin alfa HEXAL is a sterile but unpreserved product and is for single use only. 
Epoetin alfa HEXAL je sterilan lijek, ali ne sadrži konzervanse i namijenjen je samo za jednokratnu primjenu.
If you develop a serious rash or another of these skin symptoms, stop taking Epoetin alfa HEXAL and contact your doctor or seek medical attention immediately. 
U slučaju nastanka ozbiljnog osipa ili drugih kožnih simptoma, prestanite uzimati lijek Epoetin alfa HEXAL i odmah se obratite svojem liječniku ili potražite medicinsku pomoć.
Pharmacotherapeutic group: other antianaemic preparations, erythropoietin, ATC code: B03XA01. 
Farmakoterapijska skupina: ostali antianemici, eritropoetin, ATK oznaka: B03XA01 Epoetin alfa HEXAL je biosličan lijek.
Adult patients with low- or intermediate-1-risk MDS 
Odrasli bolesnici s MDS-om niskog ili srednjeg-1 rizika
Epoetin alfa HEXAL is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does. 
Epoetin alfa HEXAL pripada skupini lijekova koji potiču stvaranje crvenih krvnih stanica kao što to čini ljudski protein eritropoetin.
* Produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology For the full list of excipients, see section 6.1. 
* Proizvedeno na stanicama ovarija kineskog hrčka (CHO) tehnologijom rekombinantne DNK.
The first evidence of a response to epoetin alfa is an increase in the reticulocyte count within 10 days, followed by increases in the red cell count, haemoglobin and haematocrit, usually within 2 to 6 weeks. 
Prvi dokaz odgovora na epoetin alfa je porast broja retikulocita unutar 10 dana, praćen porastom broja crvenih krvnih stanica, hemoglobina i hematokrita,
• Nose or airway congestion. 
• Začepljnost nosa ili dišnih puteva
Epoetin alfa is a copy of the human protein erythropoietin (ee-rith-roe-po-eh-tin) and acts in the same way. 
Epoetin alfa je kopija ljudskog proteina eritropoetina i djeluje na isti način.
Epoetin alfa HEXAL contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen). 
Epoetin alfa HEXAL sadrži djelatnu tvar epoetin alfa, protein koji potiče koštanu srž da proizvodi više crvenih krvnih stanica koje sadrže hemoglobin (tvar koja prenosi kisik).
Where intravenous access is not readily available Epoetin alfa HEXAL may be administered subcutaneously. 
Kada intavenski pristup nije lako dostupan, Epoetin alfa HEXAL se može primijeniti supkutano.
• Do not attempt to inject yourself unless you have been trained to do so by your doctor or nurse. 
• Nemojte pokušavati sami sebi dati injekciju ako Vas o tome nisu posebno podučili liječnik ili medicinska sestra.
≤ 2 RBC Units >2 and ≤4 RBC Units >4 RBC Units 
≤ 2 jedinice crvenih krvnih stanica > 2 i ≤ 4 jedinice crvenih krvnih stanica > 4 jedinice crvenih krvnih stanica
An open-label, parallel-group trial in non-iron deficient adult subjects with a pretreatment haemoglobin of ≥ 10 to ≤ 13 g/dL who were scheduled for major orthopaedic hip or knee surgery compared epoetin alfa 300 IU/kg subcutaneously daily for 10 days prior to surgery, on the day of surgery and for four days after surgery to epoetin alfa 600 IU/kg subcutaneously once weekly for 3 weeks prior to surgery and on the day of surgery. 
U otvorenom ispitivanju na usporedbnim skupinama odraslih ispitanika koji nemaju nedostatak željeza s razinom hemoglobina prije početka liječenja od > 10 do ≤ 13 g/dl predviđenih za veliki elektivni ortopedski kirurški zahvat na kuku ili koljenu uspoređena je primjena 300 IU/kg epoetina alfa na dan supkutano tijekom 10 dana prije operacije, na dan operacije i još 4 dana nakon operacije s primjenom 600 IU/kg epoetina alfa supkutano jednom tjedno, 3 tjedna prije operacije i na dan operacije.
The half-life of epoetin alfa following multiple dose intravenous administration is approximately 4 hours in healthy subjects. 
Poluvijek epoetina alfa nakon intravenske primjene višekratne doze je približno 4 sata u zdravih ispitanika.
If you are receiving haemodialysis: 
Ako ste na hemodijalizi:
Other medicines and Epoetin alfa HEXAL 
Drugi lijekovi i Epoetin alfa HEXAL
Two other smaller, randomised, placebo-controlled trials failed to show a significant improvement in quality of life parameters on the EORTC-QLQ-C30 scale or CLAS, respectively. 
Druga dva manja, randomizirana, placebom kontrolirana ispitivanja nisu uspjela pokazati značajno poboljšanje parametara kvalitete života na ljestvici
This is characterised by a sustained decrease in haemoglobin despite an increase in epoetin alfa dosage (see section 4.8). 
To je karakterizirano nepekidnim sniženjem hemoglobina, usprkos povećanju doze epoetina alfa (vidjeti dio
Epoetin alfa HEXAL is used in moderately anaemic adults about to have major orthopaedic surgery (for example hip or knee replacement operations), to reduce the potential need for blood transfusions. 
Epoetin alfa HEXAL se primjenjuje u odraslih osoba s umjerenom anemijom kojima predstoji veliki ortopedski kirurški zahvat (na primjer, operacija zamjene kuka ili koljena), radi smanjivanja moguće potrebe za transfuzijama krvi.
Mildly anaemic patients (haematocrit of 33 to 39%) requiring predeposit of ≥ 4 units of blood should be treated with Epoetin alfa HEXAL 600 IU/kg intravenously, 2 times per week for 3 weeks prior to surgery. 
Liječenje odraslih kirurških bolesnika u programu autologne predonacije Blago anemične bolesnike (hematokrit od 33 do 39%) koji moraju pohraniti ≥ 4 jedinice krvi treba liječiti s 600 IU/kg Epoetin alfa HEXALa intravenski 2 puta tjedno tijekom 3 tjedna prije operacije.
Baseline Characteristics for Subjects with sEPO < 200 mU/mL at Screening 
Početne karakteristike za ispitanike sa sEPO < 200 mU/ml pri probiru
Epoetin alfa HEXAL should be administered as a subcutaneous injection. 
Epoetin alfa HEXAL treba primijeniti kao supkutanu injekciju.
• the liquid is coloured or you can see particles floating in it, 
• je tekućina obojena ili se u njoj vide plutajuće čestice,
Occlusion of the dialysis system is possible if heparinisation is not optimum. 
Ako heparinizacija nije optimalna, moguća je okluzija sustava za dijalizu.